ARROWHEAD PHARMACEUTICALS, INC. Investment Owned, at Cost
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Investment Owned, at Cost of $34.05 million as of 2014-03-31, per its 10-Q filed 2014-05-06.
Discontinued › Notes
us-gaap:InvestmentOwnedAtCost · last filed 2014-05-06
- 2014-03-31: Investment Owned, at Cost $34.05M.
- 2013-12-31: Investment Owned, at Cost $9.87M.
- 2013-09-30: Investment Owned, at Cost $1.70M; Investment Owned, at Cost as first filed $1.73M.
| Period end | Investment Owned, at Cost | Investment Owned, at Cost as first filed |
|---|---|---|
| 2014-03-31 | $34.05M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $9.87M 10-Q · filed 2014-02-04 | |
| 2013-09-30 | $1.70M 10-Q · filed 2014-05-06 | $1.73M 10-Q · filed 2014-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |